Genentech Boosts Singapore Presence With $140 Million Biologics Plant
This article was originally published in PharmAsia News
Executive Summary
Genentech will significantly increase its presence in Singapore by building a biologics manufacturing facility in the island nation for the production of its wet age-related macular degeneration treatment Lucentis (ranibizumab)